Three new studies highlight promising diabetes drug treatments to help patients who struggle with severe hyperglycemia.
New drugs show promise in treating type 2 diabetes mellitus (T2DM) patients with severe hyperglycemia, and may also lower cardiovascular disease (CVD) risks and reduce glucose variability. Here are the highlights from three new studies: a combination of saxagliptin and metformin is effective in treating severe hyperglycemia in patients with new-onset T2DM. T2DM patients treated with dipeptidyl peptidase-4 (DPP-4) inhibitors may have lower risks for CVD as compared to those for non-DPP-4 inhibitor users, except for those taking metformin. Insulin-dependent T2DM patients show reduced glucose variability when treated with a glucagon-like peptide 1 (GLP-1) agonist.
Oral Therapy for T2DM with Severe Hyperglycemia Abstract link.
Oral Antidiabetes Drugs Lead to Low CVD Risks Abstract link.
GLP-1 Agonist Reduces Glucose Variability Abstract link.